Register NOW for #ISNCON25
✅ Conference Registration isncon2025lucknow.com/registration
✅ Workshop Registration
www.isncon2025.com/workshop-registration
Pre-Conf Workshop -Critical Care Nephrology & POCUS -18th Dec 2025
📌 Free Registration for the Workshop! (But you must register for the Conference)

Insights from the CRIC Study: Visual Abstract — NephJC Based on data from the CRIC study, this analysis dives deep into whether this lab mismatch is just noise… or a clinical signal we’ve been missing. Check out the beautiful visual abstract made by our NephJC interns Sai Vani Yellampalli and Akshaya Jayachandran . Great team work!!!

Check out the VA from @drsaivani.bsky.social and @nephromommy-akshu.bsky.social on eGFRdiff in the CRIC cohort.
#Nephsky #NephJC
www.nephjc.com/news/cricdiff

We are nephrologists. Hyperkalemia is what scares endocrinologist and cardiologists.

we have the knowledge and the tools to manage this problem in this era when using the combo #NephJC

NephJC Shorts: Salt reduction still lowers BP  — NephJC JAMA 2023 Dec 19;330(23):2258-2266 doi: 10.1001/jama.2023.23651. Effect of Dietary Sodium on Blood Pressure: A Crossover Trial Deepak K Gupta ,  Cora E Lewis ,  Krista A Varady ,&nbsp...

🆕 #NephJCshort by @hswapnil.medsky.social on CARDIA SSBP trial @jama.com

🧂Shaking up an old rule: does less salt still mean less pressure?

#medsky #nephsky

www.nephjc.com/news/2025/6/...

CONFIDENCE Visual Abstract — NephJC Check out the beautiful visual abstract made by NephJC intern Michelle Fravel .

🎨Check out the beautiful #visualabstract by #NephJC intern @shelliefravel.bsky.social

⏰Chat happening on July 8, 9 pm EST

www.nephjc.com/news/2025/7/...

A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease — NephJC This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

With unshakable CONFIDENCE, finerenone and empagliflozin waltz into diabetic kidney disease - turning 'maybe someday' into 'why not today?'

#NephJC summary by @sejalplakhani.bsky.social and @jeyakumarmeyyappan.bsky.social

#MedSky

www.nephjc.com/news/confide...

🔥 BKV Infection in Kidney Transplant Recipients- A major threat to graft survival!

🎤 Don’t miss this exclusive webinar by @isn-india.bsky.social & @ttsorg.bsky.social featuring international experts🌍

🗓 8th May 2025
⏰ 7:30 PM IST

🔗 Register now: tinyurl.com/sueuuth6

@arvindcanchi.bsky.social

🎤#ISNCON2025 Preconference workshops :
🗓️18 Dec | Top faculty 🌏
🔹Intervention Nephrology
🔹Critical Care + POCUS
🔹Onconephro & Histopath
🔹Pediatric Nephrology 👶
🔹Transplant Immunology
✅ Free for delegates
⏳ Limited seats! Hurry! ➡️ 🔗 isn-india.org/isn_registrati… @isn-india.bsky.social

✨ #ISNCON2025 Lucknow Awaits!
🎖️India's Premier #Nephrology Event by @isn-india.bsky.social

🤞🏽Learn ∙ 🤝 Connect ∙ 🌟 Grow
📢 Early bird discounts (Hurry!)
🎓 50% off for students
🔗 Register now: isn-india.org/isn_registrati… @arvindcanchi.bsky.social @kajareeg.bsky.social @jasminenephro.bsky.social

🚨 Don’t miss out!
🎤 Present your work at @isn-india.bsky.social ’s flagship #ISNCON2025 in Lucknow! ✨
📢 Abstracts accepted now→ Published in 📖 IJN Publications. 🔗 Submit here 👉 isn-india.org/isn_registra...
@arvindcanchi.bsky.social @kajareeg.bsky.social @jasminenephro.bsky.social

Metformin- Should I Stay or Should I Go — NephJC This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?

Hey #NephSky & #MedSky
9pm EST 4/15/25, only on #Bluesky
Discussion on the use of metformin in advanced CKD.
Worried about lactic acidosis 💪?!
What's the evidence that an eGFR < 30 ml/min is the ideal cutoff ✂️?
Are there benefits to continuing 💊
www.nephjc.com/news/metformin-tte

Way cheaper than in western countries i meant. #NephJc. Its difficult to procure it in UAE and way costlier

its fine. as usual working hard #NephJC

its easily available and cheap #NephJC

Not all cystic kidneys = ADPKD!
Inherited & acquired mimics exist.
Don’t miss infographic by @drpallaviprasad.bsky.social! #NephJC

a cat is peeking out from behind a wooden door ALT: a cat is peeking out from behind a wooden door

Hi its shahin here. will be lurking today to learn about this topic little close to my heart #NephJC

KDIGO 2025 ADPKD Guidelines Review — NephJC This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. &nbsp;These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, ...

Happening this week!

The @kdigo.org guidelines in #ADPKD #PKD on #NephJC

www.nephjc.com/news/adpkd-k...

Summary from @brianrifkin.bsky.social

Added an addendum to this chapter:

www.rosebook.club/blog/2025/3/...

A Review of Autosomal Dominant Polycystic Kidney Disease This review discusses the pathophysiology, clinical presentation, diagnosis, treatment, and prognosis of autosomal dominant polycystic kidney disease diagnosed in adulthood.

We are discussing the @kdigo.org ADPKD guidelines tomorrow on #NephJC

Perfect timing for @jama.com to drop this review

jamanetwork.com/journals/jam...

($ub required sadly 🔒)

#NephSky

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy | NEJM A proliferation-inducing ligand (APRIL) is implicated in the pathogenesis of IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes APRIL. In this phas...

This one www.nejm.org/doi/full/10....

#NephJc

#NephJC

a small white dog is sitting in the back seat of a car looking out the window ALT: a small white dog is sitting in the back seat of a car looking out the window

Hi this is shahin.No CoI. Here to lurk and learn #NephJc

WCN'25 interview with Brad Rovin by Arvind Canchi YouTube video by International Society of Nephrology

Aha! And here's a bit about that trial (Regency/Obinutuzumab) from the one of the lead authors Dr Brad Rovin ( he's not on @bsky.app yet 🤔) #nephjc
youtu.be/DnMnTpCbFQY

Obinutuzumab in Lupus Nephritis — NephJC This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...

This week (and tonight on #NephJC) we are discussing the REGENCY trial on #obinutuzumab in SLE specifically #lupus nephritis

summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social

www.nephjc.com/news/regency...

#lupuschat #NephSky #RheumSky

daylight savings 😲

👋See you tonight (😉hope you've read the supplement) #nephjc

⏰ 9 pm EST as always

🔔For people outside North America, be mindful of timezone difference (daylight savings)

1/10
Last #NephJC we continued our Aldo streak as we discussed mineralocorticoid antagonist (MRA) withdrawal before ✅aldosterone renin ratio (ARR) & adrenal vein sampling (AVS) #NephSky #MedSky
#TenPostNephJC makes this #Endosky oriented topic easy.
pubmed.ncbi.nlm.nih.gov/39660429/

Obinutuzumab in lupus nephritis: The REGENCY Trial Visual Abstract — NephJC Is Obinutuzumab Effective and Safe in Active Lupus Nephritis?&nbsp; Check out the beautiful VA by NSMC Faculty Dr Divya Bajpai on&nbsp;the REGENCY Trial, answering the same.

It's March, 2 days before #WorldKidneyDay, so tonight there is the perfect opportunity to celebrate ( 9 pm Eastern, on 🦋)🌺🌻 #NephJC

🎨Until then, take a look at this beautiful and colorful #visualabstract made by Divya Bajpai

www.nephjc.com/news/2025/3/...

Continuous Kidney Replacement Therapies: Core Curriculum 2025 Critically ill patients that require kidney replacement therapy (KRT) are among the most ill and complex patients routinely encountered in the intensi…

Excited to see this finally in press!
Special thanks to @hswapnil.medsky.social for invitation and coauthors Abdulghani Kabli, Oleksa Rewa, Ted Clark. #canada. Special thanks to my role models Etienne Macedo and Ravi Mehta whose prior version we built upon.
#nephsky #medsky #emimcc
rb.gy/8kke9h

#NephMadness 2025: Minimal Change Disease – Beyond “Idiopathic”; Redefining Nephrotic Syndrome for the Modern Era Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025   Gabriel Miguel Cara Fuentes @carafuentes_g – @carafuentes-neph.bsky.social Dr. Cara Fuentes is an Assistant P…

#Nephmadness: “As we dissect the molecular biology of INS, … it is a fantastic time to be a (pediatric) nephrologist.“ - @carafuentes-neph.bsky.social
ajkdblog.org/2025/03/07/n...